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R“Framing” the Vessel
The Critical Importance of
Volumetric Analysis During
Serial Intravascular Imaging Studies
We read with interest the report by Tanaka et al. (1), who
undertook an important mechanistic study incorporating acetyl-
choline provocation intravascular imaging with optical coherence
tomography (OCT), which has enabled us to observe the fundamental
relationship between the morphology of the vessel wall within underlying
areas of coronary spasm in patients afflicted with vasospastic angina.
Although such observations are unique, the analytical approach used to
reach such conclusions warrants further discussion.
The investigators simply chose the frame with the most stenotic
luminal area as the representative image frame for conducting a
serial, comparative analysis of vessel wall phenotype at baseline and
after intracoronary acetylcholine and nitroglycerin administration.
Although coregistration of common vessel landmarks was under-
taken, it is somewhat difficult to achieve a precise degree of
matching of isolated frames (and thus true corresponding vessel
locations) required to make valid serial observations. Rather, the
serial matching and volumetric analysis of arterial segments de-
fined by fixed anatomical fiduciary points enables far greater
degrees of precision. As such, previously reported significant
correlations between the change in extent of coronary atheroscle-
rosis (identified from single serially “matched” intravascular ultra-
sound frames) and cardiovascular risk factors were found to be
statistically much weaker when a comparative, serial volumetric
analysis of intravascular ultrasound–derived atheroma burden in
whole coronary segments was undertaken (2,3). Although the
exquisite resolution of OCT is visually seductive, the reference
quoted by Tanaka et al. (1) for the quantitative assessment of the
ntima and media in fact never reported specific area calculations of
hese parameters (4), which are invariably seen on OCT as noncon-
iguous structures. Moreover, the development of even modest
mounts of atheroma makes identification of such structures exceed-
ngly difficult, which may result in significant intraobserver and
nterobserver variability in recording these measurements (data were
ot included in this report). The challenges in quantifying such
CT-derived structures, particularly the thickness of the fibrous cap,
ere recently outlined in an editorial by Radu and Falk (5).
Only those patients with “severe” coronary stenoses were ex-
luded from the study, and as such, no specific information on the
urden of atherosclerosis within imaged vessels was provided. This
s of particular importance, because atherosclerotic segments have
een shown to be more prone to focal coronary spasm compared
ith angiographic smooth coronary segments, which exhibit dif-
use patterns of spasm (6). Choosing to report the arterial
henotype of only the most “constricted” frame and ignoring the
henotype of neighboring segments that undoubtedly underwent
arying degrees of spasm or constriction would therefore incurelection bias. Furthermore, the frame selection for analysis in the
onspasm group was not outlined. For these reasons, a true serial
ansegmental volumetric analysis of the entire vessel downstream
o the site of intracoronary provocation would seem prudent to
inimize such bias (7). We further note that despite the “spasm”
ohort exhibiting a mean luminal area about 45% narrower than
he “nonspasm” cohort, this itself raises the possibility of “catheter-
nduced” spasm occurring in such arteries, which may have
ccurred independently of pharmacological provocation testing.
his issue would have been appropriately accounted for by per-
orming a set of control experiments with sequential OCT after
he infusion of vehicle solution in a small number of subjects (7).
Nevertheless, we believe that Tanaka et al. (1) have performed
novel set of studies to expand the utility of OCT for assessing
ynamic coronary vascular function. The immediate implications
re for the need to standardize methodologies for optical coherence
omographic image analysis and adopt analytical techniques that
epresent whole volumetric measurements as opposed to “spot”
ampling regions of interest.
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Reply
We appreciate that Dr. Puri and his colleagues have exhibited an
interest in our recent report (1) and have contributed their
comments. Because their comments bring up important points, we
would like to extend the discussion.
First, Puri et al. emphasize the superiority of the volumetric
measurements in intravascular imaging studies, compared with single-
frame analysis. Their assertion seems to be based mainly on a previous
intravascular ultrasound study that investigated the relationship be-
tween the change in plaque volume and cardiovascular risk factors (2).
lthough it may be true that for some studies, volumetric analysis is
arranted, this is not necessarily the case for our study. Before we
ndergo volumetric measurements, we first need to define the correct
easurements to make given the 3-dimensional structure. To choose
orresponding sites for comparison, we carefully coregistered the
ptical coherence tomographic (OCT) images using landmarks and
nalyzed the serial OCT frames. This procedure has been well
stablished in a variety of OCT and intravascular ultrasound studies
3) and therefore should provide valid data and results.
Second, a histology–OCT imaging comparison study by Kume
t al. (4) reported very high accuracy of OCT measurements for
ntimal plus medial area and intimal thickness. Considering that
edial area is calculated by subtracting the intimal area from
ntimal plus medial area, their results support the legitimacy of
edial area assessment by OCT imaging. We agree that medial
rea calculation should be standardized, as Puri et al. suggest.
Finally, regarding “catheter-induced spasm,” many previous spasm
tudies using coronary angiography have already reported luminal
arrowing even when asymptomatic (5). Because racial differences in
he incidence of spasm have been reported (6), we assume that some
octors in Western countries do not have enough clinical experience
ith this disease, which involves pathogenesis of a wide variety of
schemic heart diseases (7). Therefore, we would like to emphasize the
mportance of spasm in which the tunica media may play a key role.
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Antiarrhythmic Drug
Therapy in 2012
Time to Finally Open Our Eyes!
I read with interest the study by Saksena et al. (1) recently
published in the Journal. Analyzing data from the AFFIRM
(Atrial Fibrillation Follow-Up Investigation of Rhythm Manage-
ment) trial, the authors report that atrial fibrillation patients
treated with amiodarone have higher rates of death (noncardio-
vascular, in particular) and of cardiovascular hospitalization. An
adverse effect of amiodarone, especially among patients with heart
failure, had been previously observed in a subgroup analysis of the
SCD-HeFT (Sudden Cardiac Death in Heart Failure) trial (2), as
well as in retrospective analyses of the CIBIS-II (Cardiac Insuffi-
ciency Bisoprolol Study II) (3), COMET (Carvedilol or Meto-
prolol European Trial) (4), and VALIANT (VALsartan In Acute
myocardial iNfarcTion) (5) trials. Several mechanisms may be
invoked to explain these findings: iatrogenic tachy- and bradyar-
rhythmias (6), drug-induced left ventricular dysynchrony (7),
drug-drug interactions (with digoxin, for example), and extracar-
diac toxicity (thyroid, liver, lungs) (6).
A light at the end of the tunnel had been seen by many
cardiologists with the introduction in clinical practice of droneda-
rone, an iodine-free amiodarone derivate. Indeed, the ATHENA
(A Placebo-Controlled, Double-Blind, Parallel Arm Trial to
Assess the Efficacy of Dronedarone 400 mg bid for the Prevention
of Cardiovascular Hospitalization or Death from Any Cause in
Patients With Atrial Fibrillation/Atrial Flutter) trial showed a
reduction in death and hospitalization for cardiovascular causes in
patients with atrial fibrillation (8). In sharp contrast, a worrisome
increase in mortality associated with the use of dronedarone in the
setting of left ventricular systolic dysfunction was observed in the
ANDROMEDA (Antiarrhythmic Trial with Dronedarone in
Moderate to Severe congestive heart failure Evaluating Morbidity
Decrease) trial (9). More recently, the PALLAS (Permanent
Atrial fibriLLAtion outcome Study using Dronedarone on top of
